The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.
The technology could eventually have applications in pathology as well as field-based diagnostic testing for infectious diseases.
The assay analyzes a digital image of tumor tissue sample to identify ER-positive breast cancer patients who are candidates for adjuvant chemotherapy.
Sunquest now offers GeneInsight as part of its laboratory information management system solution and is working with Partners to develop new capabilities for the clinical genomics tool.
The technical-only testing service leverages Ventana's digital pathology technology.
NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.
Flagship Biosciences will use Affymetrix Quantigene ViewRNA assays as part of a new tissue-based RNA in situ hybridization analysis service.
NEW YORK (GenomeWeb News) – Definiens today said that it has raised €10 million ($12.9 million) in a private round of financing.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.
Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.
The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.
The New York Times writes that natural history museums are helping round out genetic studies with older specimens.
In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.